FDA Clearance Tracker · P210011-S002
xT CDx
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 2, 2026
Approved
Time to decision
572 days
Received Feb 7, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P210011-S002
- Device name
- xT CDx
- Applicant
- Tempus AI, Inc.
- Applicant location
- Chicago, IL
- Received
- Feb 7, 2025
- Decided
- Sep 2, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P210011
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for a Pre-specified Change Control Plan (PCCP) to modify the use of the device at a single laboratory to multiple laboratories
Source documents
Other decisions for Tempus AI, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Tempus ECG-MR510(k)
K254297 · Decided Sep 25, 2026 · 268 days after receipt
Device type: Atrial Fibrillation Risk Prediction Machine Learning-Based Notification Software (SBQ) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.